New Restricitions on Tolvaptan Use by FDA

The FDA announced new restricitions on the use of tolvaptan (SAMSCA) because of the risk of potentially fatal liver injury. The medication, which is indicated for clinically significant hypervolemic or euvolemic hyponatremia, should be used for no longer than 30 days. It should also not be used in patients with underlying liver disease, such as cirrhosis. Patients suspected of having liver injury should stop receiving tolvaptan immediately.
For more details see the FDA alert